AXLA

Axcella Health Inc. [AXLA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AXLA Stock Summary

Top 10 Correlated ETFs

AXLA


Top 10 Correlated Stocks

AXLA


In the News

11:28 29 Sep 2023 AXLA

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.

11:17 29 Sep 2023 AXLA

Are Medical Stocks Lagging Axcella Health (AXLA) This Year?

Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

09:01 29 Sep 2023 AXLA

Why Is Axcella Health (AXLA) Stock Down 24% Today?

Axcella Health (NASDAQ: AXLA ) stock is taking a beating on Friday after the biotechnology company announced plans for a reverse stock split. According to Axcella Health, shares of AXLA stock are going to undergo a one-for-25 reverse split.

09:05 29 Sep 2023 AXLA

Why Is Axcella Health (AXLA) Stock Down 21% Today?

Axcella Health (NASDAQ: AXLA ) stock is falling on Thursday following its announcement of a new Covid-19 treatment patent. However, it's not that this is bad news for the clinical-stage biotechnology company.

10:31 29 Sep 2023 AXLA

Axcella (AXLA) Up on Patent Grant for Long Covid Fatigue Drug

Axcella (AXLA) shares surge 299% after the company secures a methods-of-use patent for its lead candidate, AXA1125, which is currently under development to treat fatigue associated with Long Covid.

01:19 29 Sep 2023 AXLA

Why Is Axcella Health (AXLA) Stock Up 280% Today?

A little-known penny stock is among the market's top movers today. Axcella Health (NASDAQ: AXLA ) stock surged by as much as 280% on news that it has been granted an important new patent.

09:28 29 Sep 2023 AXLA

Axcella Health stock rockets on long Covid patent win

Axcella Health Inc (NASDAQ:AXLA) saw its stock rocket some 240% higher in Tuesday's early deals after the small-cap firm announced it had secured a patent for its treatment for ‘long' Covid fatigue. The company, in a statement, said its treatment candidate AXA1125, based on compositions of ‘endogenous metabolic modulators' (otherwise referred to as EMMs) had been granted a patent from the US Patent and Trademark Office.

08:04 29 Sep 2023 AXLA

Why Is Axcella Health (AXLA) Stock Up 68% Today?

Axcella Health (NASDAQ: AXLA ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that would act as a catalyst for today's rally.

07:35 29 Sep 2023 AXLA

Why Is Axcella Health (AXLA) Stock Up 35% Today?

Axcella Health (NASDAQ: AXLA ) stock is on the rise Wednesday as investors react to an update from the FDA. That update has to do with the company's Long Covid  Fatigue treatment currently in development.

09:28 29 Sep 2023 AXLA

Penny Stocks To Buy Now? 7 To Watch With Big News this Week

Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?

AXLA Financial details

Company Rating
Buy
Market Cap
30.51M
Income
-50.03M
Revenue
0
Book val./share
-0.03
Cash/share
0.12
Dividend
-
Dividend %
-
Employees
11
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
-10.18
Forward P/E
-
PEG
2.08
P/S
-
P/B
-225.5
P/C
84
P/FCF
-0.47
Quick Ratio
0.77
Current Ratio
0.8
Debt / Equity
-0.62
LT Debt / Equity
-
-
-
EPS (TTM)
-0.9
EPS next Y
-
EPS next Q
-
EPS this Y
-13.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.57%
-
-
-
-
SMA20
50%
SMA50
80%
SMA100
-10%
Inst Own
65.07%
Inst Trans
0.98%
ROA
-539%
ROE
4068%
ROC
20.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
2.95M
Shs Float
1.07M
-
-
-
-
Target Price
6
52W Range
2.5875-49.25
52W High
-79.43%
52W Low
+404.01%
RSI
45
Rel Volume
6.89
Avg Volume
824.62K
Volume
5.68M
Perf Week
-2.7%
Perf Month
142.89%
Perf Quarter
-11.81%
Perf Half Y
-8.36%
-
-
-
-
Beta
1.28903
-
-
Volatility
1.33%, 7.34%
Prev Close
45.88%
Price
10.0801
Change
42.58%

AXLA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-2.18-3.61-1.85-1.76-1.52
Operating cash flow per share
-1.86-3.07-1.57-1.42-1.28
Free cash flow per share
-1.9-3.07-1.58-1.43-1.29
Cash per share
4.815.543.381.440.32
Book value per share
2.943.622.370.580.08
Tangible book value per share
2.943.622.370.580.08
Share holders equity per share
2.943.622.370.580.08
Interest debt per share
1.481.70.890.730.1
Market cap
5.7B1.67B4.12B1.99B445.72M
Enterprise value
5.65B1.6B4.07B1.99B430.73M
P/E ratio
-158.09-27.79-70.04-29.67-5.41
Price to sales ratio
00000
POCF ratio
-185.67-32.7-82.76-36.73-6.41
PFCF ratio
-181.77-32.62-82.37-36.54-6.37
P/B Ratio
117.5427.6754.6590.48107.04
PTB ratio
117.5427.6754.6590.48107.04
EV to sales
00000
Enterprise value over EBITDA
-172.12-27.87-75.65-32.22-6.43
EV to operating cash flow
-183.88-31.39-81.83-36.75-6.19
EV to free cash flow
-180.02-31.3-81.44-36.57-6.15
Earnings yield
-0.01-0.04-0.01-0.03-0.18
Free cash flow yield
-0.01-0.03-0.01-0.03-0.16
Debt to equity
0.510.410.331.140.52
Debt to assets
0.30.260.230.430.11
Net debt to EBITDA
1.671.170.86-0.020.22
Current ratio
11.6211.0213.795.421.21
Interest coverage
0-16.92-17.9-21.2-25.48
Income quality
0.850.860.880.840.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.02000.010.01
Capex to revenue
00000
Capex to depreciation
-0.62-0.21-0.57-0.95-1.03
Stock based compensation to revenue
00000
Graham number
1217.159.954.781.62
ROIC
-0.44-0.69-0.56-1.36-9.2
Return on tangible assets
-0.44-0.64-0.54-1.16-4.35
Graham Net
2.793.482.30.510.04
Working capital
73.39M83.7M99.55M44.9M3M
Tangible asset value
48.51M60.22M75.38M22.01M4.16M
Net current asset value
46.97M57.92M73.12M19.33M2.38M
Invested capital
0.510.410.331.140.52
Average receivables
00000
Average payables
1.32M1.81M2.14M3.3M4.5M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.74-1-0.78-3.05-19.78
Capex per share
-0.04-0.01-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.42-0.35-0.45-0.05-0.05
Operating cash flow per share
-0.35-0.35-0.29-0.07-0.05
Free cash flow per share
-0.36-0.36-0.29-0.07-0.05
Cash per share
0.840.480.320.170.12
Book value per share
0.18-0.140.080.01-0.03
Tangible book value per share
0.18-0.140.080.01-0.03
Share holders equity per share
0.18-0.140.080.01-0.03
Interest debt per share
0.550.540.050.020.02
Market cap
2.67B2.25B445.72M884.03M401.6M
Enterprise value
2.66B2.25B430.73M873.27M394.11M
P/E ratio
-30.35-30.27-4.59-58.64-29.42
Price to sales ratio
00000
POCF ratio
-143.05-121.52-28.69-173.17-109.85
PFCF ratio
-142.76-120.19-28.65-173.17-109.85
P/B Ratio
287.19-298.01107.041.22K-177.86
PTB ratio
287.19-298.01107.041.22K-177.86
EV to sales
00000
Enterprise value over EBITDA
-129.21-133.44-39.28-208.77-115.81
EV to operating cash flow
-142.73-121.63-27.72-171.06-107.8
EV to free cash flow
-142.44-120.3-27.69-171.06-107.8
Earnings yield
-0.01-0.01-0.050-0.01
Free cash flow yield
-0.01-0.01-0.03-0.01-0.01
Debt to equity
3.02-3.650.522.46-0.62
Debt to assets
0.560.90.110.140.15
Net debt to EBITDA
0.29-0.131.372.572.2
Current ratio
2.591.231.211.050.8
Interest coverage
-27.42-20.64-28.4220.210
Income quality
0.881.040.681.281.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.46-1.56-0.1600
Stock based compensation to revenue
00000
Graham number
1.291.070.880.110.18
ROIC
-0.53-0.79-2.6-0.92-6.76
Return on tangible assets
-0.44-0.6-1.28-0.3-0.37
Graham Net
0.07-0.250.040.01-0.04
Working capital
27.23M5.12M3M646K-2.27M
Tangible asset value
9.3M-7.55M4.16M727K-2.26M
Net current asset value
3.72M-11.11M2.38M502K-2.27M
Invested capital
3.02-3.650.522.46-0.62
Average receivables
00000
Average payables
4.42M3.81M4.17M6.43M8.27M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-2.372.46-5.83-5.181.51
Capex per share
00000

AXLA Frequently Asked Questions

What is Axcella Health Inc. stock symbol ?

Axcella Health Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AXLA

Is Axcella Health Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $6. The lowest prediction is $6 and the highest is $6

What is AXLA stock prediction ?

What is Axcella Health Inc. stock quote today ?

Axcella Health Inc. stock price is $10.0801 today.

Is Axcella Health Inc. stock public?

Yes, Axcella Health Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap